Clinical trial · Interventional
Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma
Short-term Outcome of Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma
NCT03129685CI-TRIAL-00033290NRUunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assessment of short-term outcomes of ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma: single center non-randomized trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HALED | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Devascularization
- description
- Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
- interventionNames
- Procedure: HALED
Primary outcomes (1)
- measure
- Short term mortality rate
- timeFrame
- 30 day
- description
- Percentage of patients' postoperative deaths
Secondary outcomes (2)
- measure
- Short term major complications' rate
- timeFrame
- 30 days
- description
- Incidence of Clavien/Dindo grade 3 or more postoperative complications
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Review and sign informed consent; * Between 15 and 80 years of age at time of trial enrollment; * Documented pathological and/or radiological diagnosis of hepatocellular carcinoma; * Radiologically documented tumor size of \> 5 centimeters; * Radiologically documented liver cirrhosis. Exclusion Criteria: * American Anesthesia Association (ASA) Class IV or V and/or any contraindications to general anesthesia; * Uncontrollable ascites; * Deep persistent jaundice; * Hepatic encephalopathy; * Coagulopathy; * Severe thrombocytopenia; * Unable or unwilling to attend follow up visits and examinations; * Other associated surgical procedure;
References
Publications (1)
- DERIVEDElsanousi OM, Mohamed MA, Salim FH, Adam EA. Selective devascularization treatment for large hepatocellular carcinoma: Stage 2A IDEAL prospective case series. Int J Surg. 2019 Aug;68:134-141. doi: 10.1016/j.ijsu.2019.06.014. Epub 2019 Jun 29. PMID 31265917